Academic Bibliography

 Search 200 years of publications by Ghent University researchers.
Advanced search
1 file | 2.44 MB
Add to list
  1. Search results
  2. 272nd ENMC international workshop : 1...

272nd ENMC international workshop : 10 years of progress : revision of the ENMC 2013 diagnostic criteria for inclusion body myositis and clinical trial readiness. 16-18 June 2023, Hoofddorp, The Netherlands

James B Lilleker, Elie Naddaf, Christiaan G J Saris, Jens Schmidt, Marianne de Visser, Conrad C Weihl, Jan De Bleecker (UGent) and [missing] 272nd ENMC Workshop Participants
(2024) NEUROMUSCULAR DISORDERS. 37. p.36-51
Author
Organization
Abstract
Since the publication of the 2013 European Neuromuscular Center (ENMC) diagnostic criteria for Inclusion Body Myositis (IBM), several advances have been made regarding IBM epidemiology, pathogenesis, diagnostic tools, and clinical trial readiness. Novel diagnostic tools include muscle imaging techniques such as MRI and ultrasound, and serological testing for cytosolic 5'-nucleotidase-1A antibodies. The 272nd ENMC workshop aimed to develop new diagnostic criteria, discuss clinical outcome measures and clinical trial readiness. The workshop started with patient representatives highlighting several understudied symptoms and the urge for a timely diagnosis. This was followed by presentations from IBM experts highlighting the new developments in the field. This report is composed of two parts, the first part providing new diagnostic criteria on which consensus was achieved. The second part focuses on the use of outcome measures in clinical practice and clinical trials, highlighting current limitations and outlining the goals for future studies.
Keywords
Inclusion body myositis, Diagnostic criteria, Outcome measures, Clinical trials, CYTOSOLIC 5'-NUCLEOTIDASE 1A, IDIOPATHIC INFLAMMATORY MYOPATHIES, DOUBLE-BLIND, PHYSICAL-ACTIVITY, SKELETAL-MUSCLE, PREVALENCE, TDP-43, AUTOANTIBODIES, MITOCHONDRIAL, ACCUMULATION

Downloads

  • Download
    (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 2.44 MB

Citation

Please use this url to cite or link to this publication:

MLA
Lilleker, James B., et al. “272nd ENMC International Workshop : 10 Years of Progress : Revision of the ENMC 2013 Diagnostic Criteria for Inclusion Body Myositis and Clinical Trial Readiness. 16-18 June 2023, Hoofddorp, The Netherlands.” NEUROMUSCULAR DISORDERS, vol. 37, 2024, pp. 36–51, doi:10.1016/j.nmd.2024.03.001.
APA
Lilleker, J. B., Naddaf, E., Saris, C. G. J., Schmidt, J., de Visser, M., Weihl, C. C., … 272nd ENMC Workshop Participants, [missing]. (2024). 272nd ENMC international workshop : 10 years of progress : revision of the ENMC 2013 diagnostic criteria for inclusion body myositis and clinical trial readiness. 16-18 June 2023, Hoofddorp, The Netherlands. NEUROMUSCULAR DISORDERS, 37, 36–51. https://doi.org/10.1016/j.nmd.2024.03.001
Chicago author-date
Lilleker, James B, Elie Naddaf, Christiaan G J Saris, Jens Schmidt, Marianne de Visser, Conrad C Weihl, Jan De Bleecker, and [missing] 272nd ENMC Workshop Participants. 2024. “272nd ENMC International Workshop : 10 Years of Progress : Revision of the ENMC 2013 Diagnostic Criteria for Inclusion Body Myositis and Clinical Trial Readiness. 16-18 June 2023, Hoofddorp, The Netherlands.” NEUROMUSCULAR DISORDERS 37: 36–51. https://doi.org/10.1016/j.nmd.2024.03.001.
Chicago author-date (all authors)
Lilleker, James B, Elie Naddaf, Christiaan G J Saris, Jens Schmidt, Marianne de Visser, Conrad C Weihl, Jan De Bleecker, and [missing] 272nd ENMC Workshop Participants. 2024. “272nd ENMC International Workshop : 10 Years of Progress : Revision of the ENMC 2013 Diagnostic Criteria for Inclusion Body Myositis and Clinical Trial Readiness. 16-18 June 2023, Hoofddorp, The Netherlands.” NEUROMUSCULAR DISORDERS 37: 36–51. doi:10.1016/j.nmd.2024.03.001.
Vancouver
1.
Lilleker JB, Naddaf E, Saris CGJ, Schmidt J, de Visser M, Weihl CC, et al. 272nd ENMC international workshop : 10 years of progress : revision of the ENMC 2013 diagnostic criteria for inclusion body myositis and clinical trial readiness. 16-18 June 2023, Hoofddorp, The Netherlands. NEUROMUSCULAR DISORDERS. 2024;37:36–51.
IEEE
[1]
J. B. Lilleker et al., “272nd ENMC international workshop : 10 years of progress : revision of the ENMC 2013 diagnostic criteria for inclusion body myositis and clinical trial readiness. 16-18 June 2023, Hoofddorp, The Netherlands,” NEUROMUSCULAR DISORDERS, vol. 37, pp. 36–51, 2024.
@article{01HYN7BRY5ZG2B027E294TGB7Z,
  abstract     = {{Since the publication of the 2013 European Neuromuscular Center (ENMC) diagnostic criteria for Inclusion Body Myositis (IBM), several advances have been made regarding IBM epidemiology, pathogenesis, diagnostic tools, and clinical trial readiness. Novel diagnostic tools include muscle imaging techniques such as MRI and ultrasound, and serological testing for cytosolic 5'-nucleotidase-1A antibodies. The 272nd ENMC workshop aimed to develop new diagnostic criteria, discuss clinical outcome measures and clinical trial readiness. The workshop started with patient representatives highlighting several understudied symptoms and the urge for a timely diagnosis. This was followed by presentations from IBM experts highlighting the new developments in the field. This report is composed of two parts, the first part providing new diagnostic criteria on which consensus was achieved. The second part focuses on the use of outcome measures in clinical practice and clinical trials, highlighting current limitations and outlining the goals for future studies.}},
  author       = {{Lilleker, James B and Naddaf, Elie and Saris, Christiaan G J and Schmidt, Jens and de Visser, Marianne and Weihl, Conrad C and De Bleecker, Jan and 272nd ENMC Workshop Participants, [missing]}},
  issn         = {{0960-8966}},
  journal      = {{NEUROMUSCULAR DISORDERS}},
  keywords     = {{Inclusion body myositis,Diagnostic criteria,Outcome measures,Clinical trials,CYTOSOLIC 5'-NUCLEOTIDASE 1A,IDIOPATHIC INFLAMMATORY MYOPATHIES,DOUBLE-BLIND,PHYSICAL-ACTIVITY,SKELETAL-MUSCLE,PREVALENCE,TDP-43,AUTOANTIBODIES,MITOCHONDRIAL,ACCUMULATION}},
  language     = {{eng}},
  pages        = {{36--51}},
  title        = {{272nd ENMC international workshop : 10 years of progress : revision of the ENMC 2013 diagnostic criteria for inclusion body myositis and clinical trial readiness. 16-18 June 2023, Hoofddorp, The Netherlands}},
  url          = {{http://doi.org/10.1016/j.nmd.2024.03.001}},
  volume       = {{37}},
  year         = {{2024}},
}
Altmetric
View in Altmetric
Web of Science
Times cited: